EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China

Lixin Guo iD, Liming Chen iD, Fan Zhao, Xiaoyun Liu, Hongcheng Ding, Kun Wang, Xing Zhong, Vinay Babu Shankarappa, Gaurav Chaudhary

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Lixin Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glycemic Control, Insulin, Long-Acting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate glycaemic control in Chinese adults with type 2 diabetes (T2D) initiating, or switching to insulin degludec/insulin aspart (IDegAsp), a co‐formulation of basal, and bolus insulin, in a real‐world setting. Materials and Methods A 20‐week, prospective, single‐arm, open‐label, non‐interventional study was conducted in Chinese adults with T2D initiating, or switching to IDegAsp after anti‐hyperglycaemic treatment with oral antidiabetic drugs (OADs), other insulins, or glucagon‐like peptide‐1 receptor agonists. The primary endpoint was a change in HbA 1c from baseline to end of the study; the secondary endpoints included a change in fasting plasma glucose and Diabetes Treatment Satisfaction Questionnaire (DTSQ) score.

Results

Significant reductions were observed in mean HbA 1c and fasting plasma glucose, among both the overall population ( N = 878; −1.27%‐points [95% CI: −1.36; −1.19]; p < 0.0001, and −1.61 mmol/L [95% CI: −1.81; −1.41]; p < 0.0001, respectively), and in subgroups switching from OADs only, or basal, or premix insulins ± OADs. The mean total DTSQ score increased from 26.4 (baseline) to 31.6 (end‐of‐study). No significant, or unexpected tolerability, or safety issues were observed. Significant reductions were observed in incidence rates of non‐severe (rate ratio 0.37 [95% CI: 0.24; 0.59]; p < 0.0001) and nocturnal non‐severe (rate ratio 0.45 [95% CI: 0.21; 0.94]; p = 0.0326) hypoglycaemic episodes.

Conclusions

In a broad, real‐world Chinese population of adults with T2D, initiating or switching to IDegAsp was associated with improved glycaemic control and lower rates of hypoglycaemia. The use of IDegAsp could be an effective treatment option for those with suboptimal glycaemic control or therapeutic inertia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlycemic ControlInsulin, Long-ActingHumansFemaleMaleMiddle AgedChinaProspective StudiesGlycated HemoglobinBlood GlucoseAgedDrug SubstitutionDrug CombinationsHypoglycemiaAdultTreatment OutcomePatient Satisfaction

Stichwörter der Autor:innen

Chinafasting plasma glucoseglycaemic controlhaemoglobin A1c (HbA1c)hypoglycaemiainsulin analoguestype 2 diabetes

Substanzen

Hypoglycemic AgentsGlycated HemoglobinBlood GlucoseInsulin, Long-Actinginsulin degludec, insulin aspart drug combinationDrug Combinationshemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
  • The People's Hospital of Jiangmen, Jiangmen, China.
  • The Second Hospital of Chifeng, Chifeng, China.
  • Hubei University of Medicine, Shiyan, China.
  • Endocrinology Department, Jiangning Hospital affiliated to Nanjing Medical University, Nanjing, China.

ORCID-Profile: Lixin Guo, Liming Chen

Förderung

  • Novo Nordisk

Zitieren

APA

Guo, L., Chen, L., Zhao, F., Liu, X., Ding, H., Wang, K., Zhong, X., Shankarappa, V. B., & Chaudhary, G. (2025). Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16139

Vancouver

Guo L, Chen L, Zhao F, Liu X, Ding H, Wang K, et al. Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16139

BibTeX
@article{Guo2025,
  author = {Guo, Lixin and Chen, Liming and Zhao, Fan and Liu, Xiaoyun and Ding, Hongcheng and Wang, Kun and Zhong, Xing and Shankarappa, Vinay Babu and Chaudhary, Gaurav},
  title = {Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16139}
}
Kostenlos starten →